Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.

about

Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations

P2860

Q36306467-DC26CF76-30B4-4999-9631-E57E5822A4F4

P2860

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.

Item

http://www.wikidata.org/entity/Q36106171

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@ast

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@en

type

Item

label

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@ast

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@en

prefLabel

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@ast

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@en

P1476

Transient ischemic attacks as ...... c myeloproliferative neoplasm.

@en

P2093

Antigoni Mamara

http://www.w3.org/2001/XMLSchema#string

Fani Kalala

http://www.w3.org/2001/XMLSchema#string

Maria Ioannou

http://www.w3.org/2001/XMLSchema#string

Matthaios Speletas

http://www.w3.org/2001/XMLSchema#string

P2860

The risk of thrombosis in essential thrombocythemia and polycythemia vera

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.

WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.

The JAK2 V617F mutation and thrombosis.

Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis.

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.

Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.

P304

e12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4081/HR.2012.E12

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229554900

http://www.w3.org/2001/XMLSchema#string

P698

22826794

http://www.w3.org/2001/XMLSchema#string

P932

3401133

http://www.w3.org/2001/XMLSchema#string

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.

about

P2860

P2860

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932